Monopar Therapeutics MNPR Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's short-term investments?
- Monopar Therapeutics (MNPR) reported short-term investments of $52.37M in Q1 2026.
- How has Monopar Therapeutics's short-term investments changed year-over-year?
- Monopar Therapeutics's short-term investments increased by 32.5% year-over-year, from $39.51M to $52.37M.
- What is the long-term trend for Monopar Therapeutics's short-term investments?
- Over 3 years (2022 to 2025), Monopar Therapeutics's short-term investments has grown at a 71.0% compound annual growth rate (CAGR), from $12.18M to $60.88M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.